Joaquim Bellmunt

机构：Dana-Farber Cancer Institute · ORCID：0000-0003-2328-3421

发表论文 1137 篇 · 总被引 68377 次 · h-index 108

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 143)
• Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial (2025 · Annals of Oncology · 被引 93)
• Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial (2024 · ESMO Open · 被引 38)
• Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts (2025 · Nature Communications · 被引 24)
• Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma (2025 · American Society of Clinical Oncology Educational Book · 被引 19)
• Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study (2025 · European Urology · 被引 11)